Unicycive said the FDA has issued another so-called complete response letter regarding its resubmitted application for oxylanthanum carbonate for the treatment of hyperphosphatemi ...
New online hub gives commercial brokers plug-and-play resources, client-ready explainers, and white-label tools for weather-exposed accounts ...
Exceptional sales converted the limited-time May placement into a recurring everyday program in 309 clubs, validating BranchOut's innovation strategy and differentiated product portfolio ...
It’s a real commercial win but not a new revenue stream out of nowhere,” one analyst said of the new risk claim greenlit by ...
AstraZeneca announces positive results from MULBERRY phase III trial of efzimfotase alfa, an investigational enzyme replacement therapy: Cambridge, UK Tuesday, June 30, 2026, 11:0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results